Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Medicare for All will collapse innovation – cost controls will cut biopharma profit and incentive for development

Henry Grabowski and Richard Manning JUNE 2, 2017 Drug Prices And Medical Innovation: A Response To Yu, Helms, and Bach https://www.healthaffairs.org/content/forefront/drug-prices-and-medical-innovation-response-yu-helms-and-bach

Essentially, the authors imply that the US price premium could be significantly reduced without affecting research and development investments or having other adverse effects. This is a strikingly bold and unfounded conclusion. There is no sound economic rationale to suggest that price ratios across countries or revenue premiums in the United States should match current research and development spending. Hence, the fact that price differences and research and development spending levels fail this arbitrary test does not offer a basis for sound policy making.

The issue of drug prices is always controversial, but in today’s politically charged environment, it seems particularly important to carefully evaluate this post’s methods and conclusions—and to do so through the lens of the economic principles that drive companies to search for new medicines and set prices for them. Thought leaders and policy makers would be well advised to approach this issue with a clear-eyed view of facts and underlying principles that govern economic behavior.

The Authors Have A Fundamental Misunderstanding Of The Research And Development Investment Process

The research and development investment process in pharmaceuticals is Only a small proportion of new drug candidates that enter clinical trials (around 10 percent) become new drug introductions. It generally takes more than a decade for the maker of a new drug to perform the costly trials and gain Food and Drug Administration approval, and there is uncertainty concerning a drug’s efficacy and safety at every stage of the process.

Economic models of investment behavior under uncertainty indicate that spending will be driven by the expected future gains from these investments. If US policy makers were to enact regulations that drive prices down significantly, as Yu and her colleagues suggest, many projects that now have positive expected returns would no longer be profitable. Current prices would be lower but so would the expected level of future innovation.

A recent analysis by  published in Health Affairs is instructive in this regard. The authors found that research and development investment in pharmaceuticals generally provides competitive returns historically commensurate with other risky investment activities, but there is high variability across products and over time. They also observed a downward trend in pharmaceutical industry returns for the most recent cohorts, a period when research and development investments have plateaued or even declined for many firms.

Another failing of the Yu and colleagues analysis is that they analyze research and development investment in isolation from all other activities and expenses associated with new product development and commercialization. These include the costs of production, management, distribution, and provision of information about clinical trial results to physicians and payers. When these other expenses are included along with research and development costs, taxes, and the need for risk-adjusted returns to investors, as in the Berndt and related studies, there is no “excess premium” beyond what is needed to maintain current research and development investment levels as implied by Yu and her colleagues.

Drug Price Determinations In The United States And The Other Benchmark Countries

The US Market-Based System

Ultimately, market-based drug prices will reflect the value and benefits they provide to patients. Drug manufacturers conduct pharmacoeconomic studies to demonstrate the cost-effectiveness of their new drug introductions. In the United States, insurance companies and other agents that administer private employer plans and government insurance plans such as  evaluate these studies and negotiate prices and access conditions. They use various market-oriented instruments in this process, including formulary placements and copayment tiers, rebates, prior authorizations, and step therapy.

In this market setting, a new medicine that solves health problems more effectively, or that solves a problem that previously could not be solved, will tend to command a higher price than its alternatives. This explains why new therapies, such as the recently launched hepatitis C drugs, are able to sell at a high price. The new hepatitis C drugs offer something important and valuable that existing therapies simply did not offer. The sellers of these drugs did not charge high prices because they had spent a lot on research and development; they were able to set high prices because the products generated remarkable new value to patients (and to the health care systems that would be less likely to have to pay for higher-cost medical interventions in the future).

It is important, but often ignored, that there were multiple contestants in the race to bring these new drugs to market. As succeeding companies have introduced competing hepatitis C drugs, prices have fallen because customers have alternatives to which they can turn if the sellers do not negotiate lower prices (typically in the form of discounts and rebates). The incentives of market-based prices drive invention, which in turn drives prices down. In the case of the first hepatitis C drug, , for example, average rebates to Medicaid and the Department of Veterans Affairs, which receive best-price discounts, resulted in price reductions of more than 50 percent when competitive therapies entered the market.

Sign in to recut, update, or save this card.